Sweden's Orexo is pocketing $10 million from an upfront payment it will reap as part of a three-year, $585 million development pact with J&J's drug arm. The collaboration centers on preclinical small molecule drug candidates Orexo has been working on for asthma, COPD as well as other inflammatory conditions. And Orexo says it stands to gain more than $21 million in research funding from Ortho-McNeil-Janssen Pharmaceuticals and Janssen Pharmaceutica. Orexo release